Compare AbbVie Inc (ABBV) vs Amplify Cybersecurity ETF (HACK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Amplify Cybersecurity ETF — how do they compare? AbbVie Inc trades at $248.26 (market cap $438.19B), while Amplify Cybersecurity ETF trades at $119.21. The key difference: AbbVie Inc pays a 2.79% dividend while Amplify Cybersecurity ETF pays none, and Amplify Cybersecurity ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | HACK | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $119.19 |
52-Week Low | $197.38 | $70.69 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.44, up 0.57% today, with a bullish technical signal and strong support near $243. The company reported revenue of $61.16B in 2025, with net income of $4.23B, and has beaten EPS estimates for three consecutive quarters. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying interest.
Outlook remains positive with a consensus price target of $281.33, though high P/E of 70.05 and looming patent cliffs in the 2030s present risks. Revenue growth is driven by Skyrizi and Rinvoq, offsetting Humira declines, supporting a buy-rated stance amid cautious optimism for sustained expansion.
HACK is trading at $115.42, up 1.97% with strong bullish momentum from moving averages. The ETF recently hit a 52-week high and is positioned to benefit from escalating cybersecurity spending, which is forecast to exceed $300 billion in 2026. Technical indicators show the stock is near resistance at $116 with RSI suggesting mild overbought conditions. Institutional interest is growing, with D.A. Davidson increasing its position by 44.8% in Q1 2026.
The outlook remains positive as AI-driven cyber threats fuel demand for cybersecurity solutions. Key risks include market volatility and competitive pressures from other cybersecurity ETFs. Analyst sentiment is bullish with the ETF capturing the full cybersecurity stack as enterprises increase digital defense budgets amid rising AI-powered threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →
